首页> 外文会议>Cell culture engineering conference >LEVERAGING A TECHNICAL PARTNERSHIP TO DELIVER HIGH TITER BIOLOGICS MANUFACTURING
【24h】

LEVERAGING A TECHNICAL PARTNERSHIP TO DELIVER HIGH TITER BIOLOGICS MANUFACTURING

机译:利用技术合作伙伴关系来提供高滴度的生物制剂

获取原文

摘要

Biogen has two of the best legacy manufacture facilities in Research Triangle Park, North Carolina and Hillerod, Denmark, and are able to maintain many well-established partnerships with different companies, who utilize these facilities and work collaboratively to bring many products to market. Biogen not only delivers extraordinary performance in technology transfer, engineering instrumentation, and manufacturing operation, but also has a very strong technical development platform that can generate high biologies titer in the internal and biosimilar programs. Among partnership-based manufacturing experiences, some molecules have high clinical demand but relatively low titer output, which can require high volume and frequency in manufacture capacity; this low output might also require partners to engage more than one CMO and complicate the technology transfer and supply chain. Biogen has thus invested technical development resources in upstream, downstream and analytical development, all working together to develop high titer processes in numerous programs. Regardless of the challenge of multiple different cell lines which originally required different medium and processes, Biogen has shown the ability to successfully triple the titer and maintain comparable product quality in the new development. This collaboration not only utilizes the strength from each side of the partnership, but also exchanges the expertise from technical teams, facilitates technology transfer, enhances the manufacturing support and opens more capacity in the manufacturing facilities for the other programs in need.
机译:百健公司在北卡罗莱纳州的三角研究园和丹麦的希勒罗德拥有两个最好的传统制造工厂,并且能够与不同的公司保持许多良好的合作关系,后者利用这些设施并共同努力将许多产品推向市场。 Biogen不仅在技术转让,工程仪器和制造操作方面具有非凡的性能,而且还具有非常强大的技术开发平台,可以在内部程序和生物仿制药程序中产生很高的生物滴度。在基于合作伙伴关系的制造经验中,一些分子具有较高的临床需求,但滴度输出相对较低,这可能需要高容量和高频率的制造能力;这种低产出可能还需要合作伙伴参与多个CMO,并使技术转让和供应链复杂化。因此,百健公司已在上游,下游和分析开发方面投入了技术开发资源,所有这些工作共同致力于在众多计划中开发高滴定度的工艺。不管最初需要不同培养基和工艺的多种不同细胞系面临的挑战,Biogen在新开发的产品中都显示出能够成功将效价提高三倍并保持可比产品质量的能力。这种合作不仅利用了合作伙伴双方的实力,而且还交流了技术团队的专业知识,促进了技术转让,增强了制造支持,并为其他需要的计划提​​供了更多的制造设施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号